Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

T De Witte, D Bowen, M Robin… - Blood, The Journal …, 2017 - ashpublications.org
An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …

Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome

N Kröger - Blood, The Journal of the American Society of …, 2012 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (SCT) is well accepted as a curative
treatment approach for younger patients with myelodysplastic syndrome (MDS) and has …

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia

ZY Lim, R Brand, R Martino, A van Biezen… - Journal of Clinical …, 2010 - ascopubs.org
Purpose This study was performed to examine the characteristics of transplant activity for
patients with myelodysplastic syndromes (MDS) older than 50 years within the European …

[HTML][HTML] Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS

AT Gerds, TA Gooley, EH Estey, FR Appelbaum… - Biology of Blood and …, 2012 - Elsevier
Although allogeneic hematopoietic cell transplantation (HCT) has proven curative potential
for myelodysplastic syndrome, relapse after HCT remains a problem. Pretransplantation …

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

HJ Deeg, BL Scott, M Fang… - Blood, The Journal …, 2012 - ashpublications.org
Clonal cytogenetic abnormalities are a major risk factor for relapse after hematopoietic cell
transplantation (HCT) for myelodysplastic syndrome (MDS). We determined the impact of the …

Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant

Y Wang, HX Wang, YR Lai, ZM Sun, DP Wu, M Jiang… - Leukemia, 2016 - nature.com
Encouraging results from a small sample of patients with myelodysplastic syndrome (MDS)
undergoing haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) must …

[HTML][HTML] Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic …

T Schroeder, N Wegener, M Lauseker… - Biology of Blood and …, 2019 - Elsevier
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment
for patients with advanced myelodysplastic syndrome (MDS) and secondary acute …

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

W Saber, CS Cutler, R Nakamura… - Blood, The Journal …, 2013 - ashpublications.org
Allogeneic hematopoietic cell transplantation (HCT) from human leukocyte antigen (HLA)
matched related donor (MRD) and matched unrelated donors (MUD) produces similar …

[HTML][HTML] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review

DM Oliansky, JH Antin, JM Bennett, HJ Deeg… - Biology of Blood and …, 2009 - Elsevier
Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the
therapy of myelodysplastic syndromes (MDS) in adults is presented and critically evaluated …

[HTML][HTML] Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts

SA Yahng, M Kim, TM Kim, YW Jeon, JH Yoon… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Hypomethylating treatment (HMT) has been suggested as a feasible bridge to hematopoietic
stem cell transplantation (HSCT), but controversies exist around influences of HMT response …